David Williams

This inventor holds 10 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 1 EPO patent. Top assignees: The University of British Columbia, British Columbia Cancer Agency Branch, Cava Healthcare Inc.. Active years: 2012-2026.

USPTO Granted Patents = 10 (Patent Applications = 1)

% Patents Active = 70.0

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 5.2

ph-index = 2

Forward Citations = 37(Granted Patents)

Company Filing History:

5 out of 959

The University of British Columbia

patents

3 out of 66

British Columbia Cancer Agency Branch

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12643899 - Antiviral agents, uses thereof and methods for their preparation (2026-06-02),

2. 12011421 - Curcuphenol compounds for increasing MHC-I expression (2024-06-18),

3. 11197832 - Curcuphenol compounds for increasing MHC-I expression (2021-12-14),

4. 10751296 - Curcuphenol compounds for increasing MHC-I expression (2020-08-25),

5. 9862667 - Diglycidic ether derivative therapeutics and methods for their use (2018-01-09),

6. 9487479 - Small molecule inhibitors of N-terminus activation of the androgen receptor (2016-11-08),

7. 8765994 - Ship 1 modulators (2014-07-01),

8. 8686050 - Diglycidic ether derivative therapeutics and methods for their use (2014-04-01),

9. 8497123 - Sterol glucoside toxins (2013-07-30),

10. 8148336 - Sterol glucoside toxins (2012-04-03),

Title: The Innovative Contributions of David Williams

Introduction

David Williams is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of immunology, particularly in the development of curcuphenol compounds. With a total of 10 patents to his name, Williams has focused on enhancing the immunogenicity of diseased cells, such as cancer cells.

Latest Patents

One of Williams' latest patents involves the use of curcuphenol compounds to increase the expression of major histocompatibility complex class I (MHC-I) antigen in cells. This innovation is particularly relevant for cancer treatment, as it aims to improve the visibility of cancer cells to the immune system. The methods provided in this patent include pharmaceutical compositions that utilize curcuphenol compounds, which can be used alone or in combination with other therapies to treat various cancers.

Career Highlights

Throughout his career, David Williams has worked with esteemed institutions such as the University of British Columbia and the British Columbia Cancer Agency Branch. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Williams has had the opportunity to work alongside notable colleagues, including Raymond John Andersen and Mike Leblanc. These collaborations have further enriched his research and innovations in the field of immunology.

Conclusion

David Williams stands out as an influential inventor whose work has the potential to transform cancer treatment through innovative methods. His dedication to enhancing the immune response against cancer cells is commendable and highlights the importance of continued research in this vital area.